Vaxxinity Inc
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial … Read more
Vaxxinity Inc (VAXX) - Net Assets
Latest net assets as of March 2024: $13.41 Million USD
Based on the latest financial reports, Vaxxinity Inc (VAXX) has net assets worth $13.41 Million USD as of March 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($44.31 Million) and total liabilities ($30.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $13.41 Million |
| % of Total Assets | 30.26% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 13.39 |
Vaxxinity Inc - Net Assets Trend (2019–2023)
This chart illustrates how Vaxxinity Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vaxxinity Inc (2019–2023)
The table below shows the annual net assets of Vaxxinity Inc from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $13.41 Million | -78.43% |
| 2022-12-31 | $62.18 Million | -51.66% |
| 2021-12-31 | $128.62 Million | +247.20% |
| 2020-12-31 | $-87.38 Million | -80.11% |
| 2019-12-31 | $-48.51 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vaxxinity Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30928800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $278.00K | 2.07% |
| Other Comprehensive Income | $8.00K | 0.06% |
| Other Components | $374.76 Million | 2794.84% |
| Total Equity | $13.41 Million | 100.00% |
Vaxxinity Inc Competitors by Market Cap
The table below lists competitors of Vaxxinity Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ESGL Holdings Limited Warrants
NASDAQ:ESGLW
|
$1.27 Million |
|
Knusford Bhd
KLSE:5035
|
$1.27 Million |
|
ELIA SYSTEM OP. (E4S.SG)
STU:E4S
|
$1.27 Million |
|
Tomer Energy Royalties 2012 Ltd
TA:TOEN
|
$1.27 Million |
|
EXXON MOBIL - Dusseldorf Stock Exchang
DU:XONA
|
$1.27 Million |
|
WILDCAT PRETR.LS -000028
F:8Y6
|
$1.27 Million |
|
Ucommune International Ltd
NASDAQ:UK
|
$1.27 Million |
|
Valora Effekten Handel AG
F:VEH
|
$1.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vaxxinity Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 62,177,000 to 13,409,000, a change of -48,768,000 (-78.4%).
- Net loss of 56,934 reduced equity.
- Other comprehensive income increased equity by 205,000.
- Other factors decreased equity by 48,916,066.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-56.93K | -0.42% |
| Other Comprehensive Income | $205.00K | +1.53% |
| Other Changes | $-48.92 Million | -364.8% |
| Total Change | $- | -78.43% |
Book Value vs Market Value Analysis
This analysis compares Vaxxinity Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.47x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.39 | $0.05 | x |
| 2020-12-31 | $-0.70 | $0.05 | x |
| 2021-12-31 | $1.03 | $0.05 | x |
| 2022-12-31 | $0.49 | $0.05 | x |
| 2023-12-31 | $0.11 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vaxxinity Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.30x
- Recent ROE (-0.42%) is above the historical average (-45.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.37 Million |
| 2020 | 0.00% | -7173.61% | 0.01x | 0.00x | $-31.22 Million |
| 2021 | -106.65% | -207840.91% | 0.00x | 1.30x | $-150.04 Million |
| 2022 | -120.96% | 0.00% | 0.00x | 1.71x | $-81.43 Million |
| 2023 | -0.42% | 0.00% | 0.00x | 3.30x | $-1.40 Million |
Industry Comparison
This section compares Vaxxinity Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vaxxinity Inc (VAXX) | $13.41 Million | 0.00% | 2.30x | $1.27 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |